Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

reinnervate Ltd.

Division of ReInnervate Ltd.
www.reinnervate.com

Latest From PharmAthene Inc.

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical

Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making

PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.

Deals M & A

Oncology Captures One In Three New EU Drug Approvals In 2016

2016 saw 30 new active substances approved in the EU, in a total of 29 different products, of which 10 were for cancer indications. Also approved were a range of combinations of old and new drugs, some new uses, and a number of biosimilars and generics. 14 of the products approved during the year were for rare diseases, while eight received a conditional marketing authorization.

Approvals BioPharmaceutical

FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump

Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.

Metabolic Disorders Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • ReInnervate Ltd.
  • Senior Management
  • Ashley Cooper, CEO
    David Blain, CFO
    Stefan Przyborski, PhD, CSO
  • Contact Info
  • reinnervate Ltd.
    Phone: (44) 191 3343988
    Thomas Wright Way
    Sedgefield, TS21 3FD
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register